Ascite-solid model of prostate cancer and its morphological characteristics

Ascite-solid model of prostate cancer and its morphological characteristics

Targeted therapy and immunotherapy are considered promising novel therapies capable of increasing the effcacy of prostate cancer (PCa) treatment. The purpose of the study was to obtain and characterize TRAMP-C2 subcutaneous and ascite-solid models of prostate cancer in C57Bl/6j mice to study specifc...

Full description

Saved in:

Bibliographic Details
Main Authors:	E. A. Plotnikova, N. B. Morozova, A. V. Ryabova, G. V. Trunova, V. A. Khokhlova, V. B. Loschenov, A. A. Pankratov, A. D. Kaprin
Format:	Article
Language:	Russian
Published:	Russian Academy of Sciences, Tomsk National Research Medical Center 2023-09-01
Series:	Сибирский онкологический журнал
Subjects:	prostate cancer tramp-c2 cell line prostate specific membrane antigen ascite-solid prostate cancer model
Online Access:	https://www.siboncoj.ru/jour/article/view/2680
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Potential clinical application of the cancer antigen CA‑62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate‑specific antigen
by: Zh. R. Cherkasova, et al.
Published: (2023-03-01)

Usefulness of prostate specific antigen density in detecting prostate carcinoma: A hospital-based study in patients with prostate biopsies
by: Reshmi Shrestha, et al.
Published: (2022-03-01)

Incidence of prostate adenocarcinoma in transurethral resection of the prostate patients
by: Yahia Ghazwani, et al.
Published: (2025-01-01)

THE PROGNOSTIC VALUE OF BASELINE PSA BLOOD IN THE TREATMENT OF PROSTATE CANCER
by: A. A. Gritskevich, et al.
Published: (2017-02-01)

Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases
by: Yelin Mulati, et al.
Published: (2025-07-01)

Current biomarkers of prostate cancer
by: I. A. Aboian, et al.
Published: (2021-12-01)

Prostate cancer diagnosis and management: current practices in Africa a consultant-based survey
by: Marcella Derboise Christelle Biyouma, et al.
Published: (2025-03-01)

An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: A pictorial essay
by: Esmail Jafari, et al.
Published: (2020-07-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

Prostate Cancer Screening: Is it Recommended in 2024?
by: Dr. Ali Thwaini
Published: (2024-12-01)

Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study
by: Antonio Benito Porcaro, et al.
Published: (2015-10-01)

Association of Serum PSA, fPSA, and CEA Levels with Prognosis and Clinicopathological Characteristics in Prostate Cancer
by: Ahamed Y, et al.
Published: (2025-08-01)

MOLECULAR IMAGING AND INTRAOPERATIVE RADIONAVIGATION IN PROSTATE CANCER
by: P. O. Rumyantsev, et al.
Published: (2021-08-01)

USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01)

Low Testosterone Level and Mortality Risk in Patients With Prostate Cancer: A Post‐Randomization Analysis
by: Sayeh Fattahi, et al.
Published: (2025-08-01)

Updates on controversies surrounding the staging and management of newly diagnosed localized prostate cancer using prostate-specific membrane antigen (PSMA) positron emission tomography
by: Patricia Tai, et al.
Published: (2025-07-01)

The impact of exercise on prostate-specific antigen and testosterone in prostate cancer: a systematic review and meta-analysis
by: Fuxun Zhang, et al.
Published: (2025-12-01)

Diagnostic Significance of Serum Ferritin and Hepcidin as Complementary Biomarkers for Prostate Disease: A Prospective Case–Control Study in a Mission Hospital, Ghana
by: Samuel Kwasi Appiah, et al.
Published: (2025-04-01)

Use of a BMI-independent biomarker-based prostate cancer risk score to identify and triage individuals at risk of prostate disease
by: Joanne Watt, et al.
Published: (2025-07-01)

Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review
by: Minseok Suh, et al.
Published: (2024-03-01)

Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview
by: Antonela Njavro, et al.
Published: (2024-01-01)

A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer
by: Matthew J. Roberts, et al.
Published: (2025-07-01)

Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review
by: Soroush Rais-Bahrami, et al.
Published: (2025-05-01)

Effect of Glison index on survival of patients with localized prostate cancer in Samara region
by: R. D. Andreeva, et al.
Published: (2022-05-01)

CLINICAL SIGNIFICANSE OF PROSTATE-SPECIFIC ANTIGEN IN BREAST CANCER PATIENTS
by: N. S. Sergeeva, et al.
Published: (2020-12-01)

Association between the molecular markers, effect and time of response to the androgen-deprivation therapy in patients with prostate cancer
by: L. V. Spirina, et al.
Published: (2019-04-01)

68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for prostate cancer imaging: A narrative literature review
by: Jose Oliveira, et al.
Published: (2017-01-01)

Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel?
by: Kambiz Rahbar, et al.
Published: (2020-07-01)

Preclinical Evaluation of a Novel PSMA-Targeted Agent <sup>68</sup>Ga-NOTA-GC-PSMA for Prostate Cancer Imaging
by: Wenjin Li, et al.
Published: (2025-03-01)

Association Between Prostate Cancer Detection Rate and Year of Prostate Biopsy
by: Young Jun Uhm, et al.
Published: (2025-02-01)

ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer
by: Michal Staník, et al.
Published: (2025-06-01)

Benign prostatic hyperplasia and prostate-specific antigen
by: Pejčić Tomislav, et al.
Published: (2015-01-01)

COMPARATIVE EVALUATION OF CURRENT METHODS OF ANESTHESIA IN PERFORMANCE OF TRANSRECTAL PROSTATE BIOPSY
by: M. E. Topuzov, et al.
Published: (2015-10-01)

Influence of Regular Statin Intake on Prostate‐Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau)
by: Alkiviadis Papagiannakis, et al.
Published: (2025-01-01)

Metastatic bone lesions of men in combination with an increase in serum PSA from the point of view of diagnosing carcinomas of unknown primary localization
by: O. V. Poslavska, et al.
Published: (2019-05-01)

The role of glucose transporter type 1 (GLUT1) and carbonic anhydrase IX (CAIX) expression by prostate adenocarcinoma tissue in determining disease prognosis and effectiveness of radical treatment
by: S. V. Vovdenko, et al.
Published: (2023-01-01)

Clinicoradiological profile and treatment outcomes in prostate cancer at a tertiary care cancer center in India
by: Astha Rajput, et al.
Published: (2020-01-01)

Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer
by: Yaw Ampem Amoako, et al.
Published: (2019-04-01)

Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer
by: Yaw Ampem Amoako, et al.
Published: (2019-01-01)

Advanced prostatic carcinomas with low serum levels of prostate-specific antigen
by: Cerović Snežana J., et al.
Published: (2002-01-01)